Perineal Resection of Rectum (APR/APE) — Surgical Guide for Low Rectal Cancer — Cost, Top Hospitals & Success Rates | MyMedicPlus

Perineal resection of the rectum refers to the perineal component of abdominoperineal resection (APR) — also termed abdominoperineal excision (APE) — a major colorectal surgical procedure that removes the distal rectum, anal canal, and anus en bloc, leaving the patient with a permanent end colostomy. The procedure is the standard of care for cancers of the distal rectum (typically within 5 cm of the dentate line) that involve or directly threaten the anal sphincter complex and cannot be treated with sphincter-preserving anterior resection.

The operation has two phases performed either synchronously (two surgical teams simultaneously, patient in Lloyd-Davies modified lithotomy position) or sequentially (abdominal phase completed first, then patient repositioned prone in the jackknife position for the perineal phase). The abdominal phase involves high ligation of the inferior mesenteric vessels, total mesorectal excision (TME) to the level of the pelvic floor, and fashioning of the end colostomy. The perineal phase then completes the dissection, excising the specimen from below by circumscribing the anus, dissecting through the ischioanal fossa, dividing the levator ani muscles, and removing the entire specimen.

The quality of the perineal dissection is critical to oncological outcome. Conventional APE was associated with high rates of intraoperative bowel perforation (up to 23%) and positive circumferential resection margins (CRM+) at the level of the sphincters, leading to the development of cylindrical (extralevator) APE (ELAPE), which achieves a wider radial margin by resecting the levator muscles together with the sphincter complex.

• Low rectal cancer at or below the anorectal junction
• Involves permanent end colostomy formation
• Two phases: abdominal (TME) + perineal resection
• Prone jackknife position optimises perineal access
• ELAPE reduces intraoperative perforation and positive CRM rates
• Irradiated perineal wounds have high primary closure failure rates; flap reconstruction is preferred

Perineal resection of the rectum via APE is indicated for a specific subset of colorectal and perineal conditions where sphincter-preserving surgery is oncologically inadequate or technically impossible:

Low Rectal Adenocarcinoma (Primary Indication)
Rectal cancers at or below the level of the anorectal junction (typically within 1–2 cm of the dentate line), or those involving the internal or external anal sphincter on MRI staging, cannot safely undergo low anterior resection with formation of a stapled colorectal or coloanal anastomosis. APE with perineal resection is the standard curative-intent operation in this setting. Accurate pre-operative MRI staging is mandatory to identify the sphincter relationship and plan the surgical approach.

Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy
Patients with T3/T4 or node-positive low rectal cancer typically receive pre-operative long-course chemoradiotherapy (CRT, e.g., capecitabine with 45–50.4 Gy) or short-course radiotherapy (25 Gy in 5 fractions) before surgery. The irradiated pelvis significantly increases perineal wound complication rates, favouring flap-based perineal reconstruction over primary closure.

Anal Canal Squamous Cell Carcinoma (Salvage APE)
Most anal canal squamous cell carcinomas are initially treated with Nigro-protocol chemoradiotherapy (mitomycin-C / capecitabine + 50–54 Gy CRT). APE is performed as salvage surgery for persistent or recurrent disease after CRT. Salvage APE in the setting of prior high-dose radiotherapy is technically demanding and is associated with perineal wound complication rates exceeding 60%, making flap reconstruction virtually mandatory.

• Low rectal adenocarcinoma involving or threatening anal sphincters
• Locally advanced rectal cancer not amenable to sphincter preservation after CRT
• Recurrent rectal cancer with pelvic floor involvement
• Salvage APE for persistent/recurrent anal squamous cell carcinoma post-CRT
• Severe anorectal Crohn's disease with destroyed sphincters (rare indication)
• Sarcoma or GIST of the distal rectum or anal canal

APE with perineal resection is a major abdominal and perineal operation requiring thorough pre-operative assessment to optimise patient fitness and plan the surgical approach:

Oncological Staging:
High-resolution pelvic MRI is the gold standard for local staging of rectal cancer, defining the relationship of the tumour to the internal sphincter, intersphincteric plane, external sphincter, and levator ani muscles. This determines whether APE is necessary or whether an intersphincteric resection (with internal sphincter excision but external sphincter preservation) is technically feasible. CT of chest, abdomen, and pelvis stages for distant metastatic disease. PET-CT may be used for equivocal lesions, particularly in salvage settings.

Multidisciplinary Team (MDT) Discussion:
All cases should be discussed at a specialist colorectal cancer MDT including colorectal surgeon, oncologist, radiologist, and pathologist before treatment is planned. The decision to perform APE (versus sphincter-preserving approaches or non-operative management after CRT) is made collectively based on imaging, tumour biology, and patient fitness.

Neoadjuvant Treatment:
Most patients with T3/T4 or node-positive low rectal cancer receive pre-operative CRT or short-course radiotherapy to reduce local recurrence risk and, in some cases, enable sphincter preservation. The timing of surgery after CRT is typically 8–12 weeks (long-course CRT) to allow maximal tumour response while avoiding excessive tissue fibrosis.

Fitness Assessment:
APE is a prolonged operation (3–6 hours) requiring general anaesthesia. Cardiopulmonary exercise testing (CPET) risk-stratifies patients for major surgical risk. An anaerobic threshold below 10 mL/kg/min identifies high-risk patients who may benefit from pre-operative rehabilitation (prehabilitation), including supervised exercise, nutritional optimisation, and smoking cessation.

Stoma Counselling and Marking:
Pre-operative stoma siting by a specialist stoma nurse is mandatory. Colostomy position must accommodate the patient's body habitus, skin folds, belt line, and clothing preferences, as the stoma is permanent. Psychological preparation and counselling for body image change is an integral part of pre-operative care.

The perineal component of APR has evolved substantially over the past 15 years. The key developments are: adoption of the prone jackknife position for the perineal phase, wide cylindrical excision (ELAPE), and flap-based reconstruction for the irradiated perineum.

Patient Positioning for Perineal Phase
Two main positions are used:

• Prone jackknife position: The patient is placed prone with hips flexed over a knee-chest support, buttocks taped apart, and perineum perpendicular to the floor. This provides excellent direct visualisation of the ischioanal fossa, levator ani, and presacral space. It is the preferred position for ELAPE and for reconstructive plastic surgical procedures requiring good perineal access. Requires patient repositioning after the abdominal phase.
• Lloyd-Davies (modified lithotomy) position: Used for synchronous combined abdominoperineal approaches with two surgical teams. Permits simultaneous abdominal and perineal dissection without repositioning, reducing operative time.

Conventional Narrow APE
The traditional APE involved a close dissection of the anorectal specimen through the intersphincteric plane, leaving the levator ani muscles in the pelvis. This produced a "waist" in the specimen at the sphincter level, increasing the risk of positive circumferential resection margins at the site of maximum tumour proximity and of intraoperative bowel perforation (up to 23% in some series).

Cylindrical (Extralevator) APE (ELAPE) — Current Standard
ELAPE, championed by Holm et al. (Stockholm) and endorsed by the ACPGBI (Association of Coloproctology of Great Britain and Ireland), involves resecting the levator ani muscles en bloc with the sphincter complex and mesorectum, creating a cylindrical specimen without a waist. The wider radial margin achieved by ELAPE reduces intraoperative perforation to approximately 9% (vs 23% conventional) and positive CRM rates from ~50% to ~20% in involved sphincter cancers. The ACPGBI extended APE programme has promoted ELAPE as the recommended approach for all low rectal cancers requiring APE.

Perineal Wound Closure Options
After specimen removal, a pelvic dead space is created that must be managed to prevent complications:

• Primary perineal closure: Direct suture of perineal skin and subcutaneous tissue over a drain. Acceptable in non-irradiated patients with a modest dead space. Associated with 15–25% wound breakdown in non-irradiated patients but up to 40–60% in pre-irradiated patients.
• VRAM (Vertical Rectus Abdominis Myocutaneous) flap: The gold standard for perineal reconstruction after irradiated APE. A vascularised flap of rectus abdominis muscle and overlying skin is harvested from the lower abdomen and transposed into the pelvic dead space, providing a well-vascularised tissue fill and skin closure with no tension. VRAM reduces major perineal wound complication rates from ~60% to ~25% in irradiated patients.
• Gracilis muscle flap (bilateral or unilateral): An alternative when VRAM is not available (e.g., prior abdominal surgery involving the rectus muscle). The gracilis muscle from the medial thigh is harvested on its proximal vascular pedicle and transposed into the perineum. Less tissue bulk than VRAM but avoids abdominal harvest.
• Biological mesh (e.g., Permacol): Acellular dermal matrix or collagen mesh may be used to support primary closure or as a pelvic floor reconstruction when adequate skin closure is achievable.

APE with perineal resection, when performed with a quality-assured surgical technique, achieves excellent local cancer control for low rectal cancers that cannot be treated by sphincter-preserving methods:

Local Recurrence Rates:
With total mesorectal excision (TME) principles applied to the abdominal phase and ELAPE to the perineal phase, R0 resection rates (histologically clear margins) approach 75–85% even in T3/T4 tumours with sphincter involvement. Local recurrence rates of 5–10% at 3 years are achievable in high-volume specialist centres with ELAPE technique and neoadjuvant CRT, compared to local recurrence rates of 15–30% reported in earlier series using conventional APE.

Improved Circumferential Resection Margin (CRM) Clearance:
Positive CRM is the strongest pathological predictor of local recurrence after rectal cancer surgery. ELAPE reduces positive CRM rates from approximately 50% to 20% in sphincter-involved cancers by providing a wider radial margin around the tumour. This translates into significantly improved local recurrence-free survival in registry data from the Swedish Rectal Cancer Registry and other national datasets.

Reduced Intraoperative Bowel Perforation:
Intraoperative perforation of the rectum or tumour during perineal dissection causes direct spillage of tumour cells and bacteria into the operative field, significantly worsening both oncological and infective outcomes. ELAPE's reduction of perforation from 23% to approximately 9% is one of the most clinically significant quality improvements in rectal cancer surgery in recent decades.

Five-Year Survival:
Overall 5-year survival for resected rectal cancer ranges from 85% (Stage I) to 55–65% (Stage III, node-positive) and 15–25% (Stage IV, metastatic). APE with curative intent in Stage I–III disease yields 5-year survival rates comparable to sphincter-preserving anterior resection in matched cohorts, confirming that the operation does not compromise long-term oncological outcome when performed with adequate technique.

• R0 resection rates of 75–85% with ELAPE in sphincter-involved T3/T4 cancers
• Local recurrence rates of 5–10% at 3 years in specialist centres
• CRM positivity reduced from ~50% to ~20% with ELAPE
• Intraoperative perforation reduced from 23% to ~9% with ELAPE
• Permanent colostomy does not adversely affect long-term survival vs sphincter-preservation

APE with perineal resection carries significant short-term and long-term morbidity. Patients must be fully counselled about the following:

Perineal Wound Complications (Most Significant Risk):
The perineal wound is the Achilles heel of APE. In non-irradiated patients, primary closure wound breakdown occurs in 15–25%. In pre-irradiated patients (the majority of low rectal cancer patients who receive neoadjuvant CRT), primary closure perineal wound complications occur in 40–60%, including wound dehiscence, infection, abscess, sinus formation, and delayed healing requiring prolonged dressing, vacuum-assisted closure (VAC) therapy, or secondary surgical debridement. VRAM flap reconstruction reduces major complication rates to approximately 25% in this setting.

Urogenital Dysfunction:
The pelvic autonomic nerves (hypogastric nerve, pelvic splanchnic nerves, nerve erigentes) are at risk during perineal and deep pelvic dissection. Injury causes:

• Bladder dysfunction: Urinary retention, incomplete bladder emptying, or incontinence in 20–40% of patients
• Sexual dysfunction: Erectile dysfunction in 40–60% of male patients; dyspareunia, vaginal dryness, and loss of orgasm in female patients

Permanent Colostomy (Expected Functional Change):
APE always results in a permanent end sigmoid colostomy. Colostomy-related complications occur in 20–35% of patients over 5 years: parastomal hernia (most common, 20–50% lifetime risk), prolapse (5–10%), stenosis, and skin irritation. Parastomal hernia may require elective or emergency repair.

Intra-Abdominal and General Complications:

• Postoperative ileus and small bowel obstruction (5–10%)
• Anastomotic or pelvic collection (2–5% where any anastomosis is formed)
• Deep vein thrombosis and pulmonary embolism (risk elevated by prolonged lithotomy or jackknife positioning)
• 30-day mortality rate: 1–3% in elective cases at high-volume centres

ELAPE-Specific Risk: Sacral Nerve Injury
The wider levator dissection in ELAPE carries a small risk of injury to the sacral nerve roots (<3%), potentially worsening bladder or lower limb function. Careful intraoperative nerve identification is essential.

Recovery from APE with perineal resection is complex and extends over several months. A structured follow-up plan is essential for wound management, oncological surveillance, and functional rehabilitation.

Enhanced Recovery After Surgery (ERAS) Protocol:
Modern colorectal units follow ERAS (Enhanced Recovery After Surgery) protocols: early mobilisation from day 1, early oral nutrition, targeted IV fluid therapy, epidural or transversus abdominis plane (TAP) block analgesia to minimise opioid use, and avoidance of routine nasogastric tubes and abdominal drains. ERAS reduces length of stay to 4–7 days for uncomplicated APE compared to 10–14 days with traditional care.

Perineal Wound Management:
Non-irradiated primary closure wounds are dressed and reviewed at 2 and 6 weeks. VRAM flap patients require flap observation for the first 24–48 hours (colour, capillary refill, Doppler check), then standard wound care. Dehisced or infected perineal wounds are managed with regular dressings, VAC (vacuum-assisted closure) therapy for large cavities, and occasionally secondary surgical closure or debridement. Wound healing in the irradiated perineum can take 3–6 months.

Colostomy Care and Rehabilitation:
Stoma nurses provide intensive education on colostomy bag changing, peristomal skin care, diet modification, and activity restrictions during the first 6–8 weeks. A review at 4–6 weeks confirms stomal function and identifies complications (hernia, prolapse, stenosis) early. Patients are fitted for support belts to reduce parastomal hernia risk.

Oncological Surveillance (ACPGBI/NICE Guidelines):

• CT chest, abdomen, and pelvis at 12 and 36 months post-resection
• Serum CEA (carcinoembryonic antigen) every 6 months for 3 years
• MRI pelvis at 12 months if concern about local recurrence
• Colonoscopy at 1 year post-resection, then 3-yearly

Psychosocial and Sexual Rehabilitation:
Body image counselling, stoma support groups (e.g., Colostomy UK), and specialist pelvic rehabilitation physiotherapy (pelvic floor exercises, biofeedback) should be offered to all patients. Sexual dysfunction should be proactively assessed and referral to a specialist sexual medicine service offered as appropriate.

APE with perineal resection is a resource-intensive procedure with significant implications for healthcare planning and patient financial considerations where private care is involved.

Procedure and Hospitalisation Costs (2025–2026):

• UK (NHS): APE for rectal cancer is fully funded under NHS for eligible UK residents. The NHS reference cost for complex colorectal resection (including APE) is approximately GBP 12,000–18,000 per inpatient episode, including theatre, anaesthesia, HDU, and ward stay. VRAM flap reconstruction adds GBP 3,000–6,000 to the episode cost.
• United States: Total hospital and professional fees for APE range from USD 30,000–80,000 depending on institution and complication rate. Minimally invasive (laparoscopic or robotic) abdominal phase adds technical costs but may reduce length of stay.
• India: INR 2,50,000–7,00,000 (approximately USD 3,000–8,500) at accredited oncology centres. India's major oncology hospitals in Mumbai, Chennai, and Delhi perform APE as part of comprehensive colorectal cancer programmes with outcomes comparable to international benchmarks.

Centre Volume and Surgical Outcomes:
Strong evidence demonstrates that centre and surgeon volume is the single strongest predictor of APE outcomes. High-volume centres (performing >20 APEs per year) achieve significantly lower positive CRM rates, lower perforation rates, lower 30-day mortality, and lower permanent colostomy complication rates than low-volume centres. NICE and ACPGBI recommend that APE for rectal cancer should be centralised to specialist centres with designated colorectal cancer MDTs.

Cost of Managing Perineal Wound Complications:
Perineal wound complications are the main driver of excess cost in APE. A single episode of major perineal wound breakdown requiring VAC therapy, prolonged dressings, and potentially secondary surgery can add GBP 5,000–15,000 or USD 10,000–30,000 to the treatment episode. VRAM flap reconstruction, though adding upfront cost, is cost-effective when compared to the downstream cost of managing primary closure complications in irradiated patients.

APE results in a permanent colostomy, which has significant quality-of-life implications. Several alternatives should always be considered before recommending APE, and some patients previously considered APE candidates can now be managed without this procedure:

Low Anterior Resection (LAR) with Coloanal Anastomosis
Where the dentate line is not directly involved by tumour and adequate distal margin can be achieved, LAR with intersphincteric resection (ISR) and hand-sewn or stapled coloanal anastomosis can preserve continence while achieving oncological clearance. High-quality MRI staging and specialist surgical technique are required. ISR is technically demanding and carries risks of anastomotic leak (5–15% at this level) and significant functional morbidity ("low anterior resection syndrome": urgency, clustering, incontinence) in many patients.

Transanal Approaches (TaTME)
Transanal total mesorectal excision (TaTME) approaches the deep pelvis through the anus as well as abdominally, improving access to the most distal rectum and potentially extending the reach of sphincter-preserving surgery in patients with narrow pelves (particularly obese male patients). TaTME has been adopted selectively in high-volume specialist centres.

Watch-and-Wait (Non-Operative Management) After CRT
Approximately 15–30% of patients with low rectal cancer achieve a complete clinical response (cCR) after long-course chemoradiotherapy on MRI and clinical assessment (rectal examination, endoscopy). Selected patients with cCR can be managed with an intensive surveillance protocol ("watch and wait") without immediate surgery. The OPRA trial and OnCoRe registry data support this approach in expert hands, avoiding both APE and colostomy in a proportion of patients who maintain sustained cCR. Close surveillance (MRI, endoscopy, CEA at 3-monthly intervals for 2 years) is mandatory as tumour regrowth occurs in 25–30% and requires salvage resection.

Local Excision (Transanal Excision / TAMIS / TEM)
For selected early-stage (T1N0, possibly T2N0 after CRT) cancers of the distal rectum and anal canal, local full-thickness excision via transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS) avoids radical resection. It is appropriate only for small, well-differentiated, non-ulcerated tumours without lymphovascular invasion, where imaging confirms node-negative disease.

Palliative Defunctioning Colostomy (Without Resection)
In patients with unresectable or metastatic rectal cancer, a defunctioning loop colostomy (without resection of the primary tumour) relieves obstruction, controls rectal bleeding, and improves quality of life without the morbidity of a major resection. This is not a curative approach but is an important palliative option in the frail or systemically unfit patient.